+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents

No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents

Clinical Gastroenterology and Hepatology 15(1): 46-52

Antiplatelet agents decrease cardiovascular events but increase gastrointestinal bleeding (GIB). Guidelines propose platelet transfusion for patients who take antiplatelet agents and have serious GIB. We investigated whether such patients are at decreased risk for rebleeding or increased risk for cardiovascular events after platelet transfusion. We performed a retrospective cohort study of patients with GIB admitted to Yale-New Haven Hospital from 2008 to 2013 who were taking antiplatelet agents and had platelet counts higher than 100 × 109/L. Cases (patients who received platelet transfusion, n = 204) were matched with controls (no platelet transfusions, n = 204) for sex, age, and GIB location. The primary outcome was recurrent GIB. Multivariable regression analyses were performed to adjust for differences in baseline characteristics. Cases and controls had similar proportions of GIB due to non-variceal upper GIB (117 of 204, 57% vs 115 of 204, 56%) and colonic GIB (80 of 204, 39% vs 81 of 204, 40%). Cases had more severe GIB than controls, which was based on lower blood pressure and hemoglobin levels and higher heart rates and the proportion admitted to intensive care. Univariate analyses showed that higher proportions of cases had major cardiovascular events (23% vs 13% for controls), died (7% vs 1% for controls), or had hospital stay longer than 4 days (47% vs 33% for controls). However, multivariable analyses showed a significant difference between cases and controls in only risk of death (odds ratio, 5.57; 95% confidence interval, 1.52-27.1). The adjusted odds ratio for recurrent bleeding was 1.47 (95% confidence interval, 0.73-3.05) for cases vs controls. The use of platelet transfusions in patients with GIB who are taking antiplatelet agents without thrombocytopenia did not reduce rebleeding but was associated with higher mortality. At least some of the increase in mortality could be due to the residual bias of an observational study, but because of the lack of benefit, we do not support the use of platelet transfusions in patients with GIB who are taking antiplatelet agents.

(PDF emailed within 0-6 h: $19.90)

Accession: 058410653

Download citation: RISBibTeXText

PMID: 27464591

DOI: 10.1016/j.cgh.2016.07.017

Related references

Tu1361 Platelet Transfusion for Acute GI Bleeding in Patients Taking Antiplatelet Agents: Is There Benefit or Harm?. Gastroenterology 150(4): S883-S884, 2016

Should Patients Receiving Antiplatelet Agents Undergo Platelet Transfusion for Acute Gastrointestinal Bleeding?. Clinical Gastroenterology and Hepatology 15(5): 789, 2016

Does Transfusion Effectively Counter Antiplatelet Agents in Patients With Gastrointestinal Bleeding?. Clinical Gastroenterology and Hepatology 15(1): 53-55, 2016

Is Platelet Transfusion Effective in Patients Taking Antiplatelet Agents Who Suffer an Intracranial Hemorrhage?. Journal of Emergency Medicine 49(4): 561-572, 2016

Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clinical Gastroenterology and Hepatology 13(5): 906-12.E2, 2016

Antiplatelet agents and proton pump inhibitors. How can the risk-benefit balance be optimized in patients at risk for cardiovascular disease and gastrointestinal bleeding?. Gastroenterologia Y Hepatologia 34(7): 478-491, 2012

Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. Journal of Gastroenterology 52(12): 1211-1220, 2017

Vitamin K, fresh frozen plasma, and platelet transfusion used to arrest progression of intracranial hemorrhage after traumatic brain injury in a patient taking anticoagulant and antiplatelet agents. Acute Medicine and Surgery 3(4): 392-396, 2016

Management of Antiplatelet Agents and Anticoagulants in Patients with Gastrointestinal Bleeding. Gastrointestinal Endoscopy Clinics of North America 25(3): 449-462, 2016

Antiplatelet agents do not impact the hospital course in patients with gastrointestinal bleeding. Journal of Clinical Gastroenterology 45(7): 583-589, 2011

Gastrointestinal endoscopy in patients taking antiplatelet agents and anticoagulants: survey of ASGE members. American Society for Gastrointestinal Endoscopy. Gastrointestinal Endoscopy 44(3): 309-316, 1996

Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurological Research 32(7): 706-710, 2011

Antiplatelet therapy during gastrointestinal bleeding: risk or benefit?. Gastroenterology 139(2): 687-689, 2010

Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Annals of Hematology 94(9): 1457-1461, 2015

Despite a mixed reactivity to antiplatelet agents, obese patients have no benefit of platelet function monitoring: insight from the ARCTIC study. European Heart Journal 34(Suppl 1): P714-P714, 2013